Discovery of a pyrrolopyrimidine (JH-II-127), a highly potent, selective, and brain penetrant LRRK2 inhibitor

ACS Medicinal Chemistry Letters

Volumn 6, Issue 5, 2015, Pages 584-589

  Hatcher, John M ^a,b   Zhang, Jinwei ^c   Choi, Hwan Geun ^a   Ito, Genta ^c   Alessi, Dario R ^c   Gray, Nathanael S ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

leucine rich repeat kinase 2; LRRK2; Parkinson's disease; pharmacokinetics

Indexed keywords

2 ANILINO 4 METHYLAMINO 5 CHLOROPYRROLOPYRIMIDINE; 5 CHLORO 4 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 2 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO]PYRIMIDINE; LEUCINE RICH REPEAT KINASE 2; MUTANT PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRROLOPYRIMIDINE DERIVATIVE; SERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CELLS BY BODY ANATOMY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC50; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; WILD TYPE;

EID: 84929310825     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00064     Document Type: Article

References (31)

1. Gandhi, P. N.; Chen, S. G.; Wilson-Delfosse, A. L. Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease J. Neurosci. Res. 2009, 87 (6) 1283-1295
2. Dorsey, E. R.; Constantinescu, R.; Thompson, J. P.; Biglan, K. M.; Holloway, R. G.; Kieburtz, K.; Marshall, F. J.; Ravina, B. M.; Schifitto, G.; Siderowf, A.; Tanner, C. M. Projected number of people with Parkinson's disease in the most populous nations, 2005 through 2030 Neurology 2007, 68 (5) 384-386
3. Rascol, O.; Payoux, P.; Ory, F.; Ferriera, J. J.; Brefel-Courbon, C.; Montastruc, J. L. Limitations of current Parkinson's disease therapy Ann. Neurol. 2003, 53, S3
4. Daniëls, V.; Baekelandt, V.; Taymans, J. M. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies Neurosignals 2011, 19 (1) 1-15
5. Healy, D. G.; Falchi, M.; O'Sullivan, S. S.; Bonifati, V.; Durr, A.; Bressman, S.; Brice, A.; Aasly, J.; Zabetian, C. P.; Goldwurm, S.; Ferreira, J. J.; Tolosa, E.; Kay, D. M.; Klein, C.; Williams, D. R.; Marras, C.; Lang, A. E.; Wszolek, Z. K.; Berciano, J.; Schapira, A. H. V.; Lynch, T.; Bhatia, K. P.; Gasser, T.; Lees, A. J.; Wood, N. W. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study Lancet Neurol. 2008, 7 (7) 583-590
6. Dachsel, J. C.; Farrer, M. J. LRRK2 and Parkinson's disease Arch. Neurol. 2010, 67 (5) 542-547
7. Greggio, E.; Cookson, M. R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions ASN Neuro 2009, 1 (1) 13-24
8. Kumar, A.; Cookson, M. R. Role of LRRK2 kinase dysfunction in Parkinson disease Expert Rev. Mol. Med. 2011, 13, e20
9. Avner Thaler, A.; Ash, E.; Gan-Or, Z.; Orr-Urtreger, A.; Giladi, N. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews J. Neural Transm. 2009, 116 (11) 1473-82
10. Deng, X.; Dzamko, N.; Prescott, A.; Davies, P.; Liu, Q.; Yang, Q.; Lee, J.-D.; Patricelli, M. P.; Nomanbhoy, T. K.; Alessi, D. R.; Gray, N. S. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat. Chem. Biol. 2011, 7 (4) 203-205
11. Ramsden, N.; Perrin, J.; Ren, Z.; Lee, B. D.; Zinn, N.; Dawson, V. L.; Tam, D.; Bova, M.; Lang, M.; Drewes, G.; Bantscheff, M.; Bard, F.; Dawson, T. M.; Hopf, C. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons ACS Chem. Biol. 2011, 6 (10) 1021-1028
12. Zhang, J.; Deng, X.; Choi, H. G.; Alessi, D. R.; Gray, N. S. Characterization of TAE684 as a potent LRRK2 kinase inhibitor Bioorg. Med. Chem. Lett. 2012, 22 (5) 1864-1869
13. Reith, A. D.; Bamborough, P.; Jandu, K.; Andreotti, D.; Mensah, L.; Dossang, P.; Choi, H. G.; Deng, X.; Zhang, J.; Alessi, D. R.; Gray, N. S. Bioorg. Med. Chem. Lett. 2012, 22 (17) 5625-5629
14. Choi, H. G.; Zhang, J.; Deng, X.; Hatcher, J. M.; Patricelli, M. P.; Zhao, Z.; Alessi, D. R.; Gray, N. S. Brain penetrant LRRK2 inhibitor ACS Med. Chem. Lett. 2012, 3 (8) 658-662
15. Estrada, A. A.; Liu, X.; Baker-Glenn, C.; Beresford, A.; Burdick, D. J.; Chambers, M.; Chan, B.K.; Chen, H.; Ding, X.; DiPasquale, A. G.; Dominguez, S.; Dotson, J.; Drummond, J.; Flagella, M.; Flynn, S.; Fuji, R.; Gill, A.; Gunzner-Toste, J.; Harris, S.; Heffron, T. P.; Kleinheinz, T.; Lee, D. W.; Le Pichon, C. E.; Lyssikatos, J. P.; Medhurst, A.; Moffat, J. G.; Mukund, S.; Nash, K.; Scearce-Levie, K.; Sheng, Z.; Shore, D. G.; Tran, T.; Trivedi, N.; Wang, S.; Zhang, S.; Zhang, X.; Zhao, G.; Zhu, H.; Sweeney, Z. K. Discovery of highly potent, selective and brain-penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) small molecular inhibitors J. Med. Chem. 2012, 55 (22) 9416-9433
16. Henderson, J. L.; Kormos, B. L.; Hayward, M. M.; Coffman, K. J.; Jasti, J.; Kurumbail, R. G.; Wager, T. T.; Verhoest, P. R.; Noell, G. S.; Chen, Y.; Needle, E.; Berger, Z.; Steyn, S. J.; Houle, C.; Hirst, W. D.; Galatsis, P. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor J. Med. Chem. 2015, 58 (1) 419-432
17. Garofalo, A. W.; Adler, M.; Aubele, D. L.; Bowers, S.; Franzini, M.; Goldbach, E.; Lorentzen, C.; Neitz, R. J.; Probst, G. D.; Quinn, K. P.; Santiago, P.; Sham, H. L.; Tam, D.; Truong, A. P.; Ye, X. M.; Ren, Z. Novel cinnoline-based inhibitors of LRRK2 kinase activity Bioorg. Med. Chem. Lett. 2013, 23 (1) 71-74
18. Franzini, M.; Ye, X. M.; Adler, M.; Aubele, D. L.; Garofalo, A. W.; Gauby, S.; Goldbach, E.; Probst, G. D.; Quinn, K. P.; Santiago, P.; Sham, H. L.; Tam, D.; Truong, A.; Ren, Z. Triazolopyridazine LRRK2 kinase inhibitors Bioorg. Med. Chem. Lett. 2013, 23 (7) 1967-1973
19. Garofalo, A. W.; Adler, M.; Aubele, D. L.; Brigham, E. F.; Chian, D.; Franzini, M.; Goldbach, E.; Kwong, G. T.; Motter, R.; Probst, G. D.; Quinn, K. P.; Ruslim, L.; Sham, H. L.; Tam, D.; Tanaka, P.; Truong, A. P.; Ye, X. M.; Ren, Z. Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors Bioorg. Med. Chem. Lett. 2013, 23 (7) 1974-1977
20. Galatsis, P.; Hayward, M. M.; Kormos, B. L.; Wager, T. T.; Zhang, L.; Stepan, A. F.; Henderson, J. L.; Kurumbail, R. G.; Verhoest, P. R. Novel 4-(substituted-amino)-7 H -pyrrolo[2,3- d ] Pyrimidines as LRRK2 Inhibitors. US20140005183A1, 2014.
21. Mikkelson, G. K.; David, L.; Watson, S.; Smith, G. P.; Williamson, D. S.; Chen, I. Aminopyridine Derived Compounds as LRRK2 Inhibitors. WO2014106612, 2014.
22. Chan, B.; Estrada, A.; Shore, D.; Sweeney, Z. Pyrazolopyridines for Treatment of Parkinsons Disease. WO2013139882, 2013.
23. Alstetter, M.; Thormann, M.; Treml, A.; Traube, N. Pyrazolo [4,3- d ] Pyrimidines Useful as Kinase Inhibitors. WO2012143144, 2012.
24. Bilodeau, M. T.; Greshock, T. J.; Kern, J. T.; Kim, B.; Mccauley, J. A.; Rada, V. L.; Rajapakse, H. A.; Sanders, J.; Stevenson, H. H. Leucine-rich Repeat Kinase Enzyme Activity. WO2012058193A1, 2012.
25. Zhou, W.; Ercan, D.; Chen, L.; Yun, C.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K.; Eck, M. J.; Gray, N. S.; Jänne, P. A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009, 462, 1070-1074
26. Beno, B. R.; Yeung, K. S.; Bartberger, M. D.; Pennington, L. D.; Meanwell, N. A. A survey of the role of noncovalent sulfur interactions in drug design J. Med. Chem. 2015, 10.1021/jm501853m
27. Dzamko, N.; Deak, M.; Hentati, F.; Reith, A. D.; Prescott, A. R.; Alessi, D. R.; Nichols, R. J. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization Biochem. J. 2010, 430, 405-413
28. Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of drug like properties ACS Chem. Neurosci. 2010, 1 (6) 435-49
29. Fuji, R. N.; Flagella, M.; Baca, M.; Baptista, M. A. S.; Brodbeck, J.; Chan, B. K.; Fiske, B. K.; Honigberg, L.; Jubb, A. M.; Katavolos, P.; Lee, D. W.; Lewin-Koh, S.-C.; Lin, T.; Liu, X.; Liu, S.; Lyssikatos, J. P.; O'Mahony, J.; Reichelt, M.; Roose-Girma, M.; Sheng, Z.; Sherer, T.; Smith, A.; Solon, M.; Sweeney, Z. K.; Tarrant, J.; Urkowitz, A.; Warming, S.; Yaylaoglu, M.; Zhang, S.; Zhu, H.; Estrada, A. A.; Watts, R. J. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung Sci. Transl. Med. 2015, 7, 273ra15
30. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C. J.; McLauchlan, H.; Klevernic, I.; Arthur, J. S.; Alessi, D. R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update Biochem. J. 2007, 408 (3) 297-315
31. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29 (11) 1046-1051